Jefferies Global Healthcare Conference
Logotype for Cogent Biosciences Inc

Cogent Biosciences (COGT) Jefferies Global Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Cogent Biosciences Inc

Jefferies Global Healthcare Conference summary

17 Nov, 2026

Regulatory and pivotal GIST evidence

  • NDAs are under FDA review; PDUFA action dates are Nov. 30, 2026 for GIST, Dec. 30, 2026 for non-advanced systemic mastocytosis, and June 29, 2027 for advanced systemic mastocytosis.

  • In PEAK, bezuclastinib plus sunitinib showed a 0.50 hazard ratio for the primary endpoint; estimated median PFS was 16.5 months vs. just over 9 months for control, with nearly double the objective response rate.

  • Average treatment duration on the PEAK combination exceeded 21 months, vs. a pre-study second-line GIST expectation of 7–8 months.

  • GIST review is under Breakthrough Therapy Designation and Real-Time Oncology Review; management expects approval and says bezuclastinib could provide long-term benefit with sunitinib.

Safety and labeling

  • Across studies from 100 mg daily in non-advanced disease to 600 mg in metastatic GIST, common events include taste changes, hair depigmentation and elevated transaminases, reported as lab abnormalities.

  • Management reported no liver failure, transplant, serious liver clinical adverse events or Hy’s Law cases; transaminases returned to baseline with or without intervention, dose reduction or, rarely, discontinuation.

  • Management supports blood-lab liver monitoring; it said the final label is uncertain and FDA precedent varies on carrying combination-partner warnings into a new drug’s label.

  • Sunitinib, the GIST combination partner, has monthly transaminase monitoring language and a boxed hepatotoxicity warning; management sees monitoring as no barrier to prescribing or use across indications.

Launch readiness and commercial strategy

  • Commercial hiring is underway, with one sales force planned to cover GIST and both mastocytosis indications; shared clinical sites allow representatives to reach distinct specialist groups at the same locations.

  • U.S. expanded access programs are open across all three indications and have drawn strong interest; transitioning EAP patients to commercial treatment is an early launch priority after approval.

  • Management expects a potentially rapid GIST launch, citing no current second-line competition and an add-on approach to generic sunitinib; mastocytosis launch efforts will emphasize patient communication and may build more slowly.

  • Brand strategy was set at NDA submission and is expected to be outlined after approval; management said one or multiple brands would not dramatically change commercial ramp or uptake.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Cogent Biosciences